Master Specialist Hematopathology (HEM4711)
for DHA Speciality

Core Concepts

Hematopathology is the specialized diagnosis of diseases of blood, bone marrow, lymph nodes, spleen, and thymus. It encompasses neoplastic (leukemias, lymphomas, plasma cell dyscrasias, myelodysplastic/myeloproliferative neoplasms) and non-neoplastic conditions (anemias, cytopenias/cytoses, infectious processes). The World Health Organization (WHO) classification is the cornerstone for diagnosis and prognostication. Diagnosis relies on a multi-modality approach integrating morphology, immunophenotyping (flow cytometry, immunohistochemistry), cytogenetics (karyotyping, FISH), and molecular studies (PCR, NGS) to establish lineage, clonality, specific genetic abnormalities, and prognosis.

Clinical Presentation

• General/B symptoms: Unexplained fever, drenching night sweats, significant weight loss.
• Cytopenias:
  • Anemia: Fatigue, pallor, dyspnea.
  • Thrombocytopenia: Bruising, petechiae, mucosal bleeding.
  • Neutropenia: Recurrent or severe infections.
• Cytoses:
  • Leukocytosis: Hyperviscosity symptoms (headache, vision changes), splenomegaly.
  • Thrombocytosis: Thrombosis or paradoxical bleeding.
• Organomegaly: Lymphadenopathy (localized/generalized), splenomegaly, hepatomegaly.
• Bone pain/fractures: Especially in plasma cell dyscrasias.
• Mass lesions: Extranodal lymphoma, extramedullary hematopoiesis.

Diagnosis (Gold Standard)

The gold standard involves an integrated diagnostic approach. Bone marrow aspirate and biopsy are critical for most leukemias, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and plasma cell dyscrasias, providing assessment of cellularity, blast percentage, presence of dysplasia, fibrosis, and abnormal infiltrates. For lymphoma, an excisional lymph node biopsy is paramount to evaluate architectural effacement and cellular morphology. Flow cytometry on blood, bone marrow, or fresh tissue provides immunophenotypic details for lineage assignment, clonality, and aberrant antigen expression, crucial for acute leukemias, chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and multiple myeloma (MM). Immunohistochemistry (IHC) on fixed tissue sections complements flow cytometry, identifying specific markers (e.g., CD30 for Hodgkin lymphoma, cyclin D1 for MCL, myeloperoxidase for AML). Cytogenetics (karyotyping, FISH) identifies chromosomal aberrations diagnostic and prognostic for many entities (e.g., t(9;22) in CML/ALL, t(15;17) in APL, del(5q) in MDS). Molecular diagnostics (PCR, NGS) detects gene mutations or rearrangements (e.g., JAK2 in MPN, NPM1/FLT3-ITD in AML, IGHV mutation status in CLL) vital for subclassification, prognosis, and guiding targeted therapies.

Management (First Line)

Management is highly personalized and dictated by precise pathological diagnosis and risk stratification. The pathologist's role is to provide the comprehensive diagnosis that enables appropriate therapeutic decision-making. Specific genetic abnormalities (e.g., t(15;17) in Acute Promyelocytic Leukemia, APL) directly indicate targeted therapy (all-trans retinoic acid - ATRA). Risk stratification systems (e.g., IPSS-R for MDS, R-ISS for MM, FLIPI for follicular lymphoma) integrate pathological findings with clinical parameters to guide intensity of therapy (watch-and-wait, conventional chemotherapy, targeted agents, or stem cell transplant). Pathologists also monitor minimal residual disease (MRD) via highly sensitive flow cytometry or molecular techniques (e.g., BCR-ABL transcript levels in CML) to assess treatment response and detect impending relapse, guiding therapy adjustments.